Seminars in Hematology
Volume 43 , Pages S3-S8 , October 2006

The Relevance of Iron in Erythropoietin-Stimulated Erythropoiesis

  • Lawrence Tim Goodnough

      Affiliations

    • Corresponding Author InformationAddress correspondence to Lawrence T. Goodnough, MD, Professor, Pathology and Medicine, Stanford University Medical Center, 300 Pasteur Dr, H-1402, Stanford, CA 94305-5626.

References 

  1. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood. 1982;60:1241–1246
  2. Crosby WH. The metabolism of hemoglobin and bile pigment in hemolytic disease. Am J Med. 1955;18:112–122
  3. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin Invest. 1969;48:454–460
  4. Crosby WH. Treatment of haemochromatosis by energetic phlebotomy; one patient’s response to the letting of 55 litres of blood in 11 months. Br J Haematol. 1958;4:82–88
  5. Coleman DH, Stevens AR, Dodge HT, Finch CA. Rate of regeneration after blood loss. AMA Arch Intern Med. 1953;92:341–349
  6. Finch CA. Perspectives in iron metabolism. N Engl J Med. 1982;306:1520–1528
  7. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96:823–833
  8. In:  Menitove J editors. Standards for Blood Banks and Transfusion Services. (ed 19).. Bethesda, MD: American Association of Blood Banks; 1999;p. 76
  9. Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy: Implications for autologous blood donor programs. J Lab Clin Med. 1990;115:28–35
  10. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA. 1988;260:65–67
  11. Kasper SM, Gerlich W, Buzello W. Preoperative red cell production in patients undergoing weekly autologous blood donation. Transfusion. 1997;37:1058–1062
  12. Kasper SM, Lazansky H, Stark C, Klimek M, Laubinger R, Börner Y. Efficacy of oral iron supplementation is not enhanced by additional intravenous iron during autologous blood donation. Transfusion. 1998;38:764–770
  13. Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, et al. Oral or intravenous iron as an adjunct to autologous blood donation in elective surgery: A randomized, controlled study. Transfusion. 1999;39:465–472
  14. Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, Crowley JP, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med. 1989;321:1163–1168
  15. Goodnough LT, Price TH, Rudnick S, Soegiarso RW. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion. 1992;32:441–445
  16. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, efficacy. Transfusion. 1994;34:66–71
  17. Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997;37:1070–1074
  18. Goodnough LT, Bravo JR, Hsueh YS, Keating LJ, Brittenham GM. Red blood cell mass in autologous and homologous blood units (Implications for risk/benefit assessment for autologous blood crossover and directed blood transfusion). Transfusion. 1989;29:821–822
  19. Goodnough LT, Price TH, Parvin CA, Friedman KD, Vogler WR, Khan N, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol. 1994;87:695–699
  20. Adamson JW. The erythropoietin-hematocrit relationship in normal and polycythemic man: Implications of marrow regulation. Blood. 1968;32:597–609
  21. Sans T, Bofil C, Joven J, Cliville X, Simo JM, Llobet X, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion. 1996;36:822–826
  22. Mercuriali F, Inghilleri G, Biffi E, Colotti MT, Vinci A, Oriani G. Epoetin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: A randomized, double-blind, placebo-controlled, dose-ranging study. Acta Haematol. 1998;100:69–76
  23. Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: Iron-deficient erythropoiesis in iron-replete subjects. Blood. 1993;81:956–964
  24. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous donors for elective orthopedic operation. J Am Coll Surg. 1994;179:171–176
  25. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med. 1995;126:57–64
  26. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: The relevance of storage iron. Vox Sang. 1998;75:128–133
  27. Biesma DH, Kraaijenhagen RJ, Poortman J, Marx JJ, van de Wiel A. The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion. 1992;32:162–165
  28. Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med. 1992;120:746–751
  29. Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez-Richter T, et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery. 1996;119:523–527
  30. Biesma DH, Van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJ. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest. 1994;24:426–432
  31. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin (Results of a combined phase I and II clinical trial). N Engl J Med. 1987;316:73–78
  32. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–46
  33. Means RT. Commentary: An anemia of chronic disease, after all?. J Investig Med. 1999;47:203
  34. Tarng DC, Huang TP, Chen TW, Yang WC. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int. 1999;69(suppl):S107–S118
  35. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25:433–439
  36. Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med. 1998;339:625–627
  37. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234–238
  38. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079–1083
  39. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease (A randomized, controlled trial). Ann Intern Med. 1997;126:782–787
  40. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche G, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Eng J Med. 1996;334:619–623
  41. Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH. Regulation of cellular iron metabolism by erythropoietin: Activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood. 1997;89:680–687
  42. Eschbach JW, Adamson JW. Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy. Kidney Int. 1999;69(suppl):S35–S43
  43. NFK-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure (National Kidney Foundation-Dialysis Outcomes Quality Initiative). Am J Kidney Dis. 1997;30(suppl 3):S192–S240
  44. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023
  45. Hamstra RD, Block MH. Erythropoiesis in response to blood loss in man. J Appl Physiol. 1969;27:503–507
  46. Beutler E. The utilization of saccharated Fe59 oxide in red cell formation. J Lab Clin Med. 1958;51:415–419
  47. Wood JK, Milner PF, Pathak UN. The metabolism of iron-dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol. 1968;14:119–129
  48. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D. The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol. 1971;21:617–622
  49. Cavill I. Disorders of iron metabolism (Diagnostic methods). Clin Haematol. 1982;11:259–273
  50. Eckfeldt JH, Witte DL. Serum iron: Would analytical improvement enhance patient outcome?. Clin Chem. 1994;40:505–507
  51. Tietz NW, Rinker AD, Morrison SR. When is a serum iron really a serum iron? (The status of serum iron measurements). Clin Chem. 1994;40:546–551
  52. Cazzola M, Pootrakul P, Bergamaschi G, Huebers HA, Eng M, Finch CA. Adequacy of iron supply for erythropoiesis: In vivo observations in humans. J Lab Clin Med. 1987;110:734–739
  53. Goodnough LT, Price TH, Rudnick S. Iron-restricted erythropoiesis as a limitation to autologous blood donation in the erythropoietin-stimulated bone marrow. J Lab Clin Med. 1991;118:289–296
  54. Hastka J, Lasserre JJ, Schwarzbeck A, Reiter A, Hehlmann R. Laboratory tests of iron status: Correlation or common sense?. Clin Chem. 1996;42:718–724
  55. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr. 1974;27:681–687
  56. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med. 1974;290:1213–1216
  57. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918–922
  58. Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg PA, Hulten L. Screening for iron deficiency: An analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. Br J Haematol. 1993;85:787–798
  59. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89:1052–1057
  60. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44:45–51
  61. Brugnara C, Colella GM, Cremins J, Langley RC, Schneider TJ, Rutherford CJ, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994;123:660–667
  62. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem. 1990;36:1350–1355
  63. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056–1063
  64. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of response. Blood. 1995;86:4446–4453
  65. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-alpha) therapy in cancer patients. Blood. 1995;85:1676–1678
  66. Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol. 1997;58:251–256
  67. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–1307
  68. Barosi G. Inadequate erythropoietin response to anemia: Definition and clinical relevance. Ann Hematol. 1994;68:215–223
  69. Thompson JA, Gilliland DG, Prchal J, Bennett JM, Larholt K, Nelson RA, et al. GM/EPO MDS Study Group Effects of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood. 2000;95:1175–1179
  70. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990;322:1693–1699
  71. Pincus T, Olson NJ, Russel IJ, Wolfe F, Harris ER, Schnitzer TJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in patients with rheumatoid arthritis. Am J Med. 1990;89:161–168
  72. Abels R, Larholt K, Krantz K, Bryant E. Recombinant human erythropoietin for the treatment of the anemia of cancer. In:  Murphy MJ editors. Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Dayton, OH: Alpha Med; 1991;p. 121–141
  73. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218–1234
  74. Glaspy J, Demetri G, Cremieux P. Does baseline endogenous erythropoietin level impact hemoglobin (Hb) response to rHuEPO in cancer patients?. Blood. 1999;94:15B
  75. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—A randomized multicenter study. Blood. 1996;87:2675–2682

PII: S0037-1963(06)00158-2

doi: 10.1053/j.seminhematol.2006.08.003

Seminars in Hematology
Volume 43 , Pages S3-S8 , October 2006

Article Tools

* Image Usage & Resolution